Chapter 3
CRISPR-Cas9 Technology for Unlocking Immunity Against Infectious Pathogens

M. Suriya
https://orcid.org/0009-0008-5398-0221
Vels Institute of Science, Technology, and Advanced Studies, India

V. Aarthi
https://orcid.org/0009-0004-0177-7716
Vels Institute of Science, Technology, and Advanced Studies, India

S. S. Meenambiga
https://orcid.org/0000-0002-5445-525X
Vels Institute of Science, Technology, and Advanced Studies, India

P. Prakash
Sathyabama Institute of Science and Technology, India

P. Vivek
Vels Institute of Science, Technology, and Advanced Studies, India

ABSTRACT

The development of CRISPR-Cas9 has dramatically changed the field of genome engineering and its utilization in epigenome editing could have profound implications for precision medicine.This ability to precisely target epigenetic marks, including DNA methylation, histone modifications, and chromatin remodeling, allows for exciting therapeutic developments in cancer, neurodegenerative and autoimmune

DOI: 10.4018/979-8-3373-4857-5.ch003

diseases. New developments such as CRISPRi, CRISPRa, and reversible CRISPR off/CRISPR on, allow for complex and multiplexed epigenetic reprogramming with improved specificity and safety. Nonetheless, there are some challenges to delivery off-target effects, stability of epigenetic modification, and moral lines, especially with inheritable epigenetic modification. The essential principles of CRISPR-Cas9-based epigenome editing, its therapeutic prospects for personalized medicine, and the consideration of technological, ethical, and policy aspects associated with epigenome editing are discussed

INTRODUCTION

Precision medicine is revolutionizing health care by enhancing the ability to personalize prevention, diagnosis, and treatment for an individual, based on their genetic, environmental, and lifestyle characteristics, with the role of gene regulation being particularly important. We can regulate genes not only at the DNA sequence level, but also at the epigenetic level as heritable, but reversible modifications, which do not change the underlying genetic code. Epigenetic dysregulation is being increasingly recognized in the pathology of an ever-expanding list of diseases, including, but not limited to, cancer, neurodegenerative diseases, autoimmune diseases, and metabolic disorders. The CRISPR-Cas9 system is based on a bacterial immune system and was developed as a genome-editing technology, and has most recently advanced to the realm of epigenome editing, which offers an exciting possibility for clinical application. Scientists have discovered that CRISPR can be coupled with a catalytically dead Cas9 (dCas9), to which the scientists then attach functional effector domains that enable targeted modulation of epigenetic marks (e.g., DNA methylation; histone modifications) in a compact and specific manner without permanently modifying the genome.

This is a significant advance over traditional epigenetic therapeutics, which often have non-specific effects that engage global epigenetic machinery. CRISPR-based epigenome editing technologies, including CRISPR interference (CRISPRi), CRISPR activation (CRISPRa), reversible systems such as CRISPRoff and CRISPRon have great potential to use in the treatment of diseases caused by aberrant expression of genes. These technologies provide an unprecedented level of precision to reprogram gene expression; thus, providing new avenues for treatments for cancers, neurodegenerative diseases, autoimmune diseases, and drug resistance. There are still challenges in developing the technology further to improve delivery efficiency, reduce off-target effects, determine the long-term stability of reversible modifications, and address ethical concerns raised in using germline editing. This chapter will provide a brief history and mechanism of CRISPR-Cas9, as this technology is applied in

epigenome editing, summarize how epigenome editing can be used in precision medicine, and critically analyze changes that will need to be made to technology, ethics, and regulatory systems prior to clinical translation. Finally, this chapter will address potential developments, including the impact of artificial intelligence and the integration of nanotechnologies, to improve the specificity, safety, and scalability of CRISPR-based therapies.

1. FUNDAMENTALS OF CRISPR-CAS9 AND EPIGENOME EDITING

The CRISPR-Cas9 system has surfaced as a groundbreaking device in genetic engineering and biomedical research. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) was first proposed as a component of the adaptive immune system in prokaryotes because CRISPR repeats enable bacteria to use the identification and subsequent cutting of foreign genetic material to defend against virus infection (Mojica & Montoliu, 2016). CRISPR relies on the action of proteins called Cas (CRISPR-associated), and the Cas9 proteins from *Streptococcus pyogenes* are the most studied proteins for applications in genome editing. In 2012, researchers Doudna and Charpentier showed that CRISPR-Cas9 could be converted into a programmable device to edit genomes in vitro, and accurately target DNA in organisms (Jinek et al., 2012). This led to many applications in gene therapy, functional genomics, and modelling disease.

In addition to conventional genome editing, CRISPR has been applied to epigenome editing: the modulation of gene expression without changing the DNA sequence. This is accomplished through the use of a catalytically inactive Cas9 (dCas9) fused to epigenetic effector domains, which facilitate the addition or removal of structures such as methylation marks on DNA or modifications to histones, all at a targeted genomic site (Liu et al., 2016). Reversible and highly targeted modulation of gene expression is one of the key advantages of epigenome editing over traditional genome editing, which results in irreversible changes to the genome. Tools like CRISPR interference (CRISPRi) or CRISPR activation (CRISPRa) can block or promote, respectively, the expression of genes at the cellular level, and these tools provide a useful platform for studying gene function and eventually for designing therapeutics (Gilbert et al., 2013).

The effective delivery of CRISPR components into cells is vital for success in both genome editing or epigenome editing.

Viral delivery systems, like adeno-associated viruses (AAVs) or lentiviruses, are often utilized because of their high efficiency of delivery especially in vivo (Lino et al., 2018) however, they have a limited capacity to deliver their payload and they

can produce immunogenicity. Non-viral systems, such as lipid nanoparticles, electroporation, and gold nanoparticles, are usually safer and more versatile systems, especially for applications in the clinic (Yin et al., 2017). Improving accurate, effective, and safe delivery methods continues to be an area of interest and research moving CRISPR-based epigenome editing technologies forward.

As researchers develop CRISPR technology, computer science, including ai, and machine learning will support guide RNA design, specificity, and predictive capabilities of CRISPR. This will be beneficial in minimizing off-target effects, and maximizing the therapeutic effects of CRISPR-Cas9. Moreover, regular dialogue should be encouraged between researchers and regulators on ethical considerations for epigenome editing especially with regards to heritable genome editing. In general, CRISPR-Cas9 will offer great opportunities for the application of epigenome editing in precision medicine, in understanding and developing novel strategies to treat diseases based on gene regulation, and also in personalized therapy.

1.1 History and Evolution of CRISPR-Cas Systems

Evidence of CRISPR-Cas systems was discovered in 1987, when researchers found repeats in the genome of *Escherichia coli* (E. coli), but did not know what they were (Ishino et al., 1987). It would be until the early 2000s before these sequences could finally be described as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and connected to an adaptive immune defense system found in bacteria and archaea. Mojica et al. (2005) discovered that these sequences contained segments of foreign genetic material (i.e. plasmids and viruses) not found in the genome, which enabled prokaryotes to recognize and defend against future attacks of foreign genetic material. Key research on related CRISPR-associated (Cas) proteins, particularly Cas9 from the bacterium *Streptococcus pyogenes*, provided an avenue for accurately targeting and hydrolyzing other DNA. This explained the mechanism by which prokaryotes were equipped with a defense mechanism, and inspired a new chapter in molecular biology and genetic engineering.

The longitude alteration happened in 2012 when Jennifer Doudna and Emmanuelle Charpentier reconstituted the CRISPR-Cas9 system in vitro and showed that it could be utilized as a programmable genome editing tool. Using CRISPR-Cas9, for example, researchers can create guide RNAs that identify DNA sequences to which the Cas9 enzyme and proteins bind and uniquely alter the genome. Since this, the CRISPR toolbox has provided many extending toolbox options, including additional tools that employ analogous systems, such as Cas12 and Cas13, which target DNA and RNA, respectively (Shmakov et al., 2017). With the ability to engineer a catalytically inactive Cas9 protein (dCas9), researchers can now employ many more applications outside genome editing that include epigenome editing,

transcription regulations, and live-cell imaging (Qi et al., 2013). The developments in the CRISPR toolset are altering the landscape of genetics research and extending options in therapeutics, agriculture, and diagnostics. CRISPR-Cas is still among the available scientific technologies and is flexible and transformative.

1.2 Mechanism of CRISPR-Cas9 Gene Targeting

CRISPR-Cas9 is a highly efficient gene editing system that has derived from a bacterial adaptive immune system that provides defense to viral infection. A synthetic single-guide RNA (sgRNA) is produced to be complementary to a designated DNA sequence in the genome. The Cas9 endonuclease will bind the target DNA with a Protospacer Adjacent Motif (PAM) sequence present, in an sgRNA specific manner. The sgRNA directs the Cas9 endonuclease to cleave at the site and induce a double-stranded break (DSB) in DNA. The sequence-specific cleavage particular to the sgRNA and the target, will activate normal repair mechanisms in the cell, specifically either non-homologous end joining (NHEJ), which may or may not be small insertions or deletions to the target, or homology directed repair (HDR), if an HDR template can be provided whereby a cell would add specificity to editing the existing DNA sequence. This significant programmability allows for the concurrent effective and precise editing of DNA sequences in research settings regarding genetics and therapeutics (Jinek et al., 2012).

1.2.1 Guide RNA (gRNA) Design and Target Recognition

Targeting genes using CRISPR-Cas9 occurs via a single guide RNA (sgRNA), an engineered version of the combination of CRISPR RNA (crRNA) and trans-activating of crRNA (tracrRNA). An sgRNA is designed to include a sequence of 20 nucleotides that contains complementarity to the target sequence of DNA, that is necessary for a sequence- specific binding plaque that will be in the presence of a PAM, such “NGG,” present at about 5' direction and from the target site in *Streptococcus pyogenes* Cas9. The PAM is essential for Cas9 binding, localisation and to cleave the region in the genome that is intended (Sternberg et al., 2014) which proves that specificity is crucial for genome editing.

1.2.2 Cas9-Mediated DNA Cleavage

Once the gRNA-Cas9 complex success-fully binds to the target DNA, the Cas9 protein undergo a conformational change leading to alignment of the two separate nuclease domains–RuvC and HNH—for cleavage of DNA. The HNH domain cleaves the strand of DNA bonded to the guide RNA and RuvC cleaves the non-

complementary strand ((3)) creating a double-strand break (DSB) in a genomic site. This targeted cleavage is essential to the CRISPR-Cas9 gene editing process because it triggers cell DNA repair processes that can be exploited to induce gene disruption or precise genetic modification (Hsu et al., 2014).

1.2.3 DNA Repair Pathways

In the case of the double-strand break (DSB) that DSB is introduced by the Cas9 protein, the cell produces one of two major DNA repair pathways to salvage genomic integrity. The second is Non-Homologous End Joining (NHEJ) which correctly connects the broken DNA ends directly but will often involve small insertions or deletions that can disrupt gene function by causing frameshift mutations. The second is Homology-Directed Repair (HDR), a more precise and less efficient form of restoration using the homologous DNA template to correct the break. HDR is useful in bringing a single sequence of DNA into sequence and is ideal for the precise creation of genomic precision. NHEJ and HDR were crucial in selecting the best candidate, as they determine if gene knockout or precise gene correction is accomplished (Cong et al., 2013).

1.3 Tools for Epigenome Editing: dCas9, CRISPRi, and CRISPRa

CRISPR technology has become far more powerful than gene editing to address epigenome editing, providing researchers with a way to modify the expression of genes, without altering DNA. dCas9 is an altered version of Cas9 that is still able to conform to DNA and is nuclease-bound and is not nuclease-bound due to RuvC and HNH domain mutations. The dCas9 protein is a coded DNA binding agent that leads to the recruitment of several epigenetic effectors to specific genomic loci to regulate gene expression precisely.

Two of the primary systems of transcriptional modulation derived from dCas9 are CRISPR interference, CRISPRi, and CRISPR activation. In CRISPRi dCas9 is fused with repressor domains such as KRAB (Kruppel-associated box) that induce heterochromatin development and suppress gene transcription (Gilbert et al., 2013). A passive system can silence gene expression, preventing transcription initiation or elongation. On the other hand, CRISPRa involves pairing dCas9 with transcriptional activators like VP64, p300 or SunTag systems that enrich gene transcription by maintaining a free chromatin state and establishing the transcriptional machinery (Chavez et al., 2015). These instruments have improved functional genomics because they allow reversible and impregnated control of gene expression without permanent and permanent genetic changes and provide useful both in the laboratory

and therapeutic applications. Next-generation CRISPR platforms are transforming precision gene and epigenetic regulation. CRISPRi and CRISPRa enable programmable repression or activation of target genes, while CRISPRoff/CRISPRon allows reversible epigenetic silencing or activation at specific loci. Multiplexed systems facilitate simultaneous regulation of multiple genes, and inducible platforms provide temporal control using chemical or light-responsive triggers. Together, these innovations expand the versatility, tunability, and reversibility of CRISPR-based regulation, offering powerful tools for functional genomics, synthetic biology, and therapeutic applications.

1.4 Differences Between Genome Editing and Epigenome Editing

Genome editing and epigenome editing are two different yet complementary approaches in the area of genetic modification, each with its mechanisms and its consequences. Genome editing, to put it simply, refers to physically altering an organism's DNA sequence. Recently developed tools, including the well-known CRISPR-Cas9, TALENs, and ZFNs, create double-strand breaks at a defined locus in the genome, and the cell takes care of repair, either through NHEJ, or HDR. In any of the cases, this process can generate permanent changes in the DNA sequence and usually leads to insertions, deletions or point mutations. Genome editing is used in therapy to precisely correct genetic defects or to disrupt the gene function (Komor et al., 2017). It holds promising applications in gene therapy, functional genomics and crop improvement. However, the use of Genome editing raises potential issues, both regarding the effects generated by off-target events, and unintended alterations across the genome.

In contrast to DNA modification, epigenome editing alters gene activity without modification of the DNA sequence. Epigenome editing utilizes catalytically inactive nucleases (for example, dead Cas9 (dCas9)), which is effectively a binder that is used with epigenetic effector domains that modify, add or remove chemical marks on DNA bases or histone proteins. These various modifications, in addition to DNA methylation, can also reflect on histone acetylation or methylation, and they induce changes in gene activity through alterations in chromatin accessibility. Techniques such as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) utilize dCas9 that is fused to transcriptional repressors (for example, the KRAB domain) or to activators (for example, the VP64 or p300) that can reversibly silence or activate gene expression at the transcriptional level. Compared to genome editing, epigenome editing is mostly reversible, which enables temporal control of gene function without any permanent genetic change. Thus, epigenome editing provides an amazing new approach for study the gene regulation and developing therapeutic strategies with

lower risk of irreversible off-target effects (Liu et al., 2016). Synthetic transcriptional regulators enable programmable control of gene expression by recruiting effector domains to specific genomic loci via dCas9. Modular activators (e.g., VPR) and repressors (e.g., KRAB-MeCP2) allow tuning of transcriptional output by combining multiple functional domains, providing precise and adjustable gene regulation. Emerging CRISPRai systems integrate activation and interference within the same cell, enabling bidirectional control of different target genes simultaneously. These innovations represent a key trend in synthetic biology, expanding the versatility and precision of CRISPR-based gene regulation.

1.5 Delivery systems: viral and non-viral vectors

An important limitation to successfully harnessing genome editing applications is the effective delivery of CRISPR-Cas9 components into target cells. Delivery systems can be classified as viral delivery and non-viral delivery vectors, both of which have their own associated pros and cons. Viral delivery is favorable due to the inherent property of viruses to infect host cells and are high efficacy to deliver genetic material. Within viral delivery, adeno-associated virus (AAV) vectors appear to be the most acceptable for in vivo utilization because of their lower immunogenicity and ability to infect dividing and non-dividing cells. However, there are limitations, including limited packaging capacity (~4.7kb) and cannot be utilized with larger nucleases. Furthermore, if AAV use a split-Cas9 system or a variant, such as SaCas9, needs to be utilized (Lino et al. 2018). Insertional mutagenesis continues to be a complicating factor, but lentiviral vectors that stably integrate into the host genome while having longer expression of Cas9 and guide RNAs can be used for ex vivo editing- in particular, for targeting immune cells or stem cells in their resident compartment (Xu et al., 2021). To align with current and emerging trends, CRISPR research is increasingly focusing on advanced platforms such as prime editors, base editors, multimodal CRISPRai systems, and epigenetic editors that enable precise, tunable gene and chromatin regulation. Non-viral delivery methods, including lipid nanoparticles and exosome-based systems, are being developed to improve tissue-specific in vivo delivery. Computational design tools facilitate optimized guide RNA selection, effector domain combination, and off-target minimization, accelerating experimental workflows. Additionally, ethical and safety considerations—including off-target effects, unintended epigenetic changes, and regulatory safeguards—are integral to responsible application and translational research. Together, these innovations define the forward trajectory of CRISPR technologies.

Adenoviral vectors have the advantages of being able to accommodate a greater cargo size and provide strong temporary expression, but have the disadvantage of being highly immunogenic. In summary, viral delivery vectors can be highly effec-

tive, but there are still significant hurdles to overcome as a result of immunogenicity, limitations in delivery vector size, lipid nanoparticles (LNPs), and potential for genomic integration (Charlesworth et al., 2019). Safety and administration of long duration of expression in space and expense recently drove recommendations of applying non-viral vectors as opposed to viral vectors. LNPs are viewed as the most advanced delivery platform, and are efficacious delivery platforms and protect from degradation through encapsulated with Cas9 mRNA and sgRNA in recent clinical trials demonstrating application of CRISPR (e.g., transthyretin amyloidosis (Gillmore et al., 2021). Polymeric nanocarriers (e.g. polyethyleneimine, chitosan) can also be complexed based on charge attraction with CRISPR cargos, but application in clinical situations is limited, as higher concentrations demonstrate cytotoxicity (Xu et al., 2021). Effective delivery is critical for translating CRISPR-based epigenome editing into therapeutic applications. Lipid nanoparticles (LNPs) enable tissue-specific delivery of CRISPR ribonucleoproteins, while exosome-mediated transport facilitates crossing biological barriers such as the blood–brain barrier. Additionally, engineered AAV vectors provide targeted, stable delivery with reduced immunogenicity. Optimizing these delivery platforms is essential to enhance efficacy, specificity, and safety of CRISPR interventions in clinical settings.

Techniques which are categorized as physical methods (e.g. electroporation, microinjection) can utilize effective ex vivo non-viral delivery strategies, particularly in isolated immune cells, and have acceptable delivery of the CRISPR systems in embryos; however, are not feasible for use in systemic (in vivo) delivery (Lino et al., 2018). More recently, metals and biologically derived mimic carriers, such as gold nanoparticles and exosomes, have demonstrated some potential for targeted delivery and improved biocompatibility (Xu et al., 2021). Although non-viral strategies are comparatively safer and offer greater flexibility than viral systems, they still struggle with high efficiency, tissue-specific targeting, and sustained expression.

In comparison, viral vectors provide greater efficacy and stable expression compared to non-viral carrier systems, while non-viral vectors address safety, scalability, and transient action which is advantageous for therapeutic applications that depend on the spatial and temporal control in gene editing processes. Currently, hybrid systems such as virus-like particle loaded Cas9 proteins, LNP-viral systems, and exosome-based carriers are being developed to overcome the drawbacks of traditional delivery methods. These approaches were developed or used with the goal of ameliorating CRISPR-Cas9's efficiency advantage while reducing issues associated with complexity of use and commercialization of CRISPR-Cas9 for clinical use (Xu et al., 2021; Gillmore et al., 2021).

Table 1. Comparative Overview of Viral and Non-Viral Delivery Systems for CRISPR-Cas9

Feature	Viral Vectors	Non-Viral Vectors
Efficiency	High	Moderate to high. It will depend on system
Cargo Size	Limited (AAV ~4.7 kb)	Flexible (large payloads possible)
Expression	Stable (lentivirus), transient (AAV)	Mostly transient
Safety	Risk of immune response, integration	Lower in risk, but variable in biocompatibility

2. APPLICATIONS IN PRECISION MEDICINE

The ability which helps to correct the disease-causing mutation and engineer cellular system with high specificity made the CRISPR-cas9 to become a cornerstone technology. The CRISPR application was extend beyond simple gene knockout, enabling the modification of in immune effector cell in the oncology. The immune effector cell is including T cell and Natural Killer (NK)cell which enhance the patient specific therapies. These NK cell helps the patient to overcome the tumor immune evasion also. For example: Crispr mediated disruption of inhibitory receptor such as PD-1 or CTLA-4 in T cell has shown promise in response of augmenting antitumor the otherside, the chimeric antigen receptor (CARs) integration, individual tumor antigen has observed the process from the development of more potent adoptive immunotherapies tailored to individual tumor antigen which was allowed by chimeric antigen receptor. To develop engineered T cell which not only attract the cancer cell but also display the developed persistent was utilised by CRISPR. It also helps to reduce the exhaustion introducing by one new major limitation of the conventional immunotherapies (Ravichandran & Maddalo, 2023). The induced pluripotent stem cell (ipSCs)was induced by the patient and it was corrected at the site of mutation and differentiate into functional tissue with the help of which edited through CRISPR. It also includes offering possibilities for autologous transplantation without making risk of immune rejection. In the disease of the neuromuscular system, it consists of Duchenne muscular dystrophy, preclinical studies using CRISPR-edited ipSCs. These are done restoration demonstration of dystrophin function. In the ophthalmology, to correct the mutation linked to the inherited retinal degenerative disease, the ex vivo genome edited should has to applied. By allowing the researcher to test pharmacological intervention on genetically accurate human tissue model, the CRISPR can able to generate the disease model which accelerate the drug screening and patient-specific organoid. It helps to shorten the translation gap between the laboratory research and clinical application, highlighting CRISPR-cas9 as one of

the most impactful technologies in achieving individualized medicine and these advances help to improve and enhance our capacity to design highly personalized treatment regimen also (Jayarajan et al., 2025).

2.1 Epigenome Editing for Cancer Therapy

Epigenome editing has emerged as a powerful strategy in cancer therapy by enabling precise and reversible control of gene expression without permanently altering the DNA sequence. The double strand break, epigenome editing utilizes catalytically inactive cas9(dcas9) which fused with epigenetic effective domain was introduced, unlike classical CRISPR-cas9 genome editing. The epigenetic effected domain includes DNA methyltransferase, histone acetyltransferase demethylases. These are used to modulate the chromatin state at targeted loci. The silencing of oncogene, the reactivation of tumor suppressor genes, the modulation of no coding regulatory elements implicated in tumor initiation and progression was allowed by this technology. For Example: The dcas9-TET1 fusion has used by targeted DNA demethylation. The expression of silenced tumor suppressor gene was restored by this fusion in commercial cancer cell. It leads to decreased level of proliferation and tumor genetically(Tejedor et al., 2023).Nowadays, the further expand in the clinical potential of epigenome editing by the advances in the nanoparticles and viral-based delivery platform was done by achieving efficient and tissue-specific targeting, thereby overcoming one of the primary barrier to therapeutic translation(Kwon & Lim, 2023).To silence the inconvenience pathway with high specificity, the dcas9-KRAB repression system has been employed, while the dcas9-p300 acetyltransferase activator enhance transcription of the protective genes. This offering programmable control over cancer epigenomes (O' Geen et al., 2019).

2.2 Neurodegenerative Disease Interventions (e.g., Alzheimer's, Parkinson's)

For the neurodegenerative disease, the promising therapeutic strategies was emerged by the CRISPR-cas9 technology. The neurodegenerative disease is such as Alzheimer disease and Parkinson disease. These editing of genes was additionally included by CRISPR mediated which shown to reduce the potential in amyloid-beta plaque accumulation, thereby mitigating synaptic dysfunction and neuronal loss (journal of Advanced Research,2021). The CRISPR-mediated editing of genes such as *APP, PSEN 1/2* and *BACE 1*. In PD, the targeting *SNCA* was approached by genome editing (alpha-synuclein) and the mutation of *LRRK 2* are being explored, this explorayi6help to suppress to aggregation of protein pathogens and help to restore the function of the dopaminergic neuron, enhancing the neuronal replacement therapy

with the stem cell-based CRISPR editing (Khatri et al., 2023). Aside from direct the gene correction. The next generation CRISPR tool was introduced. The next generation CRISPR tool are include based and prime editor. These based and prime editors are help to modify the pathway of the disease without causing double-strand break, offering more efficient application in the central nervous system (Next generation CRISPR gene editing tool, 2025). The transformative pote6level of CRISPR-cas9 is designing personalized and disease-modifying therapy for neurodegenerative condition are combined together to highlight the development (see **Fig. 1**).

Figure 1. CRISPR-Cas9 Interventions in Neurodegenerative Diseases



Figure 1. CRISPR-Cas9 Interventions in Neurodegenerative Diseases

2.3 Autoimmune and Inflammatory Disease Modulation

For the autoimmune and inflammatory diseases, the CRISPR-cas9 is being investigated increasingly as a therapeutic tool, where the chronic pathology was being derived by the dysregulated immune pathway. These has one of the most promising approaches, this promising approach involves immune cell population editing. The editing of immune cell population are T-cell, B-cell and macrophage. These are help to either enhance the regulatory mechanism or help to suppress the aberrant action

of immune or enhance regulatory mechanism. For instances, while targeted editing of pro-inflammatory cytokines which offer new possibilities for controlling systemic inflammation (Liang et al., 2022). The pro-inflammatory curvilinear are two types, they are IL-6 and TNF-a. CRISPR has been shown to modify B-cell receptor and attractive T-cell in the diseases like systemic Lucius erythematous and rheumatoid arthritis. These receptor and reactive help to reduce autoantibody production and preventing tissue destruction (Zhang et al., 2021). Furthermore, the ex vivo editing of hematopoietic stem cell and their transplantation is being developed as a long-term strategy to generate immune cell resistant to autoimmune trigger. These also offering durable remission without continues immune suppression (Schmidt et al., 2022). Finally, the versatility of CRISPR in modulating immune response, shifting the paradigm from system management towards targeted, curative intervention in autoimmune inflammatory disorder are these high lighten advancement.

2.4 Reversal of Drug Resistance through Epigenetic Reprogramming

The development of multidrug resistance (MDR)is one of the major challenges in cancer therapy, which are mostly driven by the alternated epigenetic which reprogrammed the gene expression in the tumor cell. A powerful strategy was developed by CRISPR based epigenome editing which has emerged to reverse the resistance of the drug by selectively modifying DNA methylation, histone modification and chromatin accessorily at gene implicated in resistance pathway. For Example: The transcriptional activator or repression are fused with CRISPR which can modulate the ATO-binding cassette (ABC) transporter expressions. ABC transporter is such as ABCB1 and ABCG2.These are help to contribute to enhance efflux (Huang et al., 2022). Also, for which are frequently over expressed in restaurant tumor. The two following can help to retire the sensitivity to chemotherapeutic such as targeting Justine deacetylases (HDACs) or DNA methyltransferase (DNMTs)with CRISPR-guided epigenetic Reprogramming. The chemotherapeutic are such as doxorubicin, cisplatin, and paclitaxel (Sun et al., 2023). CRISPR-mediated modulation of No coding RNAs beyond the direct gene regulation. The long Noncoding RNAs to influence the pathway of surprises and cell cycle control, it has been reported. It includes the registration of cancer cell to treatment (Li et al., 2021). Finally, these approaches highlight the potential of CRISPR epigenetic reprogramming also provide durable therapeutic response by re-establishing tumor vulnerability to conventional and targeted therapies and not only to overcome resistance of the drug.

2.4.1 CRISPR-Based Epigenetic Editing

A highly precise approach to modulate Hennessy expressions in drug-resistance cancer cell without creating permanent DNA break was offered by the CRISPR/dcas9-based epigenetics editing. It can able to selectively up regulate or downregulate the gene which drive multidrug resistance by fusing the dcas9 with transcriptional activator or repressor. One key application involves targeting ATP-binding cassette (ABC) transporter. The application is such as ABCB1 and ABCG2. It commonly over expressed in resistant tumor. It helps in the enhancement of drug efflux. To restore the sensitivity of chemotherapeutic agent, the CRISPR-mediated downregulation of this transporter has been shown, and also for effective overcoming resistance mechanism. How the programmable epigenome editing can be leveraged to fine-tune cellular pathway was the example for the strategies. By providing a reversible and targeted means to sensitive tumor cell to therapy while minimizing off-target genomic alteration (Zhao et al., 2022).

2.4.2 Targeting Epigenetic Regulators

To provide a powerful strategy to overcome drug resistance by modifying chromatin structure and gene accessibility. The epigenetic regulator was targeted by CRISPR based approaches. The researchers can alter the epigenetic landscape of tumor cell, reactive silenced tumor suppressor Gennie and inhibit pathway that contribute to chemoresistance by directing dcas9 to Justine deacetylases (HDACs) or DNA methyltransferase (DNMTs). To commonly used chemotherapeutic for sensitive resistance cancer cell, the modulation has been shown. The chemotherapeutic include doxorubicin, violating and paclitaxel, restoring apoptosis and cell cycle control. Importantly, such targeted epigenetic editing enables the selective intervention without permanent DNA damage, reducing off-target effect while achieving durable therapeutic benefits. The combining of CRISPR-mediated HDAC or DNMT regulation with conventional chemotherapy was demonstrated by these studies. This combined process can significantly able to improve the outcome of the treatment in the preclinical cancer models (Kim et al., 2020).

2.4.3 Noncoding RNA Modulation

A versatile platform for modulating the Following RNAs including microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) was provided by CRISPR technology. These two can play a critical role in the regulation of apoptosis to the chemoresistance with an aberrant expression. The RNAs is linked oftener to the chemoresistance as they can influence drug efflux, DNA repair, and anti-apoptotic

signaling. The researchers have successfully reversed the resistance mechanism and restored the sensitivity to chemotherapeutic agent by using CRISPR/dcas9-based activator or repressor to specifically upregulate or downregulate the miRNAs and lncRNAs. The targeting mir-21, lncRNA HOT AIR, and other resistance -associated Noncoding RNAs. It was targeted through CRISPR-mediated modulator. This modulation can significantly able to resensitize tumor cell to drug such as cisplatin and paclitaxel, these are high lightly the therapeutic potential of this approach (Chen et al., 2022). The therapeutic mir-21, lncRNA HOT AIR and other resistance associated Noncoding RNAs are demonstrated by the preclinical studies.

2.4.4 Clinical Implications

For overcoming multidrug resistance and improve therapeutic outcome, the integration of CRISPR-based epigenetic reprogramming into clinical oncology holds the significant promises. To transition resistant tumor while minimizing off-target effect, the epigenetic regulator, Noncoding RNAs, CRISPR technologies offer a targeted and programmable approaches by precisely modulating the gene expression. To potentially converting refractory cancer into responsive ones, these strategies can be combined with the conventional therapies, targeted agent or immunotherapies to achieve synergistic effect. The recent advancements in delivery system are including viral vector, lipid nanoparticles, and ex vivo edited cell, are facilitated safe and efficient application in patient, moving CRISPR epigenetic intervention closer to clinical translation. The effect of the drug reduced tumor progression and improved the survival of subjects in an experimental model, demonstrating the clinical utility of environmental modification in the conceptual framework of precision oncology (Patel et al., 2023). These clinical utilities have been enhanced by demonstrating in studies with early pre-clinical or transnational studies.

2.5 Use in Regenerative Medicine and Stem Cell Therapy

By enabling the precise corrections of diseases-causing mutation, enhancement of cellular function and controlled differentiation by the advances in genome editing have revolutionized regenerative medicine and stem cell therapy. The modification of the target's genome allows repair of genetic defect prior to differentiate into specialized cell type. They are cardiomyocytes, neuron or pancreatic β-cell. These offering the potential for apologies transplantation with decreased immune rejection. Additionally, improving differentiation efficiency and integration into damaged tissue is enhanced by the modulation of transcription factor and signaling pathway which guide stem cell fate. Preclinical studies have demonstrated that genetically corrected stem cell response function in model of Duchenne muscular dystrophy, Parkinson's disease,

and retinal degenerative disease (Zhao et al., 2022). The regenerative potential was enhanced by the epigenetic reprogramming in stem cell. It works by activating protective gene and suppressing senescence pathway, promoting survival, engraftment and functional recovery in vivo. Coupled with advanced delivery platform are the cornerstone of the next generation regenerative therapies (Liu et al., 2023; Moreno et at., 2021). These platforms are such as viral vector, lipid nanoparticles and biomaterial scaffold. These approaches provide safe and effective strategies for tissue repair, positioning of the genome and epigenome editing.

3. TECHNOLOGICAL ADVANCEMENTS AND METHODOLOGIES

The scope and precision of genome and epogenome editing, transforming, research and therapeutic application which are significantly expanded by the advancement of technology nowadays. This advancement has new innovation techniques and complementary methodology. The new innovation techniques are such as innovation in CRISPR-C as system (base editor, prime editor, cas varient). The complementary methodology has a high fidelity cas nuclease, engineered guide RNAs and computational off target prediction tool. In addition, it involves improvements with advanced delivery ranging from viral vector to non-viral vector method. The viral vector is such as adeno-associated virus (AAVs). The non-viral vectors such as lipid nanoparticles, electroporation techniques which has specific tissue, in-vivo application facilitation. Collectively these technology and methodology improvement help to transform genome editing. (Doudna & Charpentier, 2023; Anzalone et al., 2020).

3.1 Development of dCas9-Fusion Proteins

The engineering of catalytically inactive cas9(dcas9) are fused to the functional effected used, so either it can be repressed or active target gene. The promotion of heterochromatin formation is done by the recruiting chromatin modifying complexes. The targeted gene activated through localized Justine acetylation and it was facilitated by p300 just one acetyltransferase domain. Recent advances in CRISPR technology have enabled epigenetic editing using dCas9-based fusions with effector domains. Targeted delivery of TET1 or DNMT3A allows site-specific DNA demethylation or methylation, while p300 and HDAC fusions enable precise histone acetylation or deacetylation, modulating transcription at specific loci. Additionally, multimodal editors (epi-BE/dual-function editors) combine base editing (ABE or CBE) with epigenetic effectors, allowing simultaneous correction of genetic mutations and restoration of local chromatin states. These tools expand the functional scope of CRISPR, providing fine-tuned control over gene expression and epigenetic

landscapes for both research and therapeutic applications. As much as the development of dcas9-effector and multiplexed targeting strategies, there is an increase of versality and enabling the pathway with high precision which simultaneously enabled. It maintains the balance of both sequences. The functional toolkit is not only expanded by this approach but also reduces traditional gene editing method risk. It has a reversible intervention process in both the research and therapeutic application. It ensures the safer intervention process (Thakore et al., 2015). Recent advancements (2020–2025) in CRISPRi and CRISPRa include dCas9-SunTag systems, which use peptide arrays to recruit multiple effector proteins, significantly amplifying transcriptional activation or repression. Multi-effector recruitment scaffolds, such as SunTag, MoonTag, and SSSavi, allow combinatorial or modular recruitment of activators, repressors, and epigenetic modifiers to a single locus, enhancing efficiency and epigenetic footprint. These systems improve the magnitude, specificity, and tunability of CRISPR-mediated gene regulation compared to simple dCas9-effector fusions.

3.2 Single-Cell and Spatial Epigenomics Integration

There is a great revolution in the study of genome regulation in the recent advances of single cell and spatial epigenomic by making unprecedented resolution in gene expressions and chromatin state at the cell level of the individual. The research allows the perturb specific genes by integrating the CRISPR-based tool with single cell technology. In the other side, the spatial epigenomic and the dimension of tissue architecture, enabling the mapping of epigenetic modification, which is particularly valuable for complex tissue and developing organ. There is a specific regulatory network process was introduced. The researcher may dissect the multilayered gene regulatory mechanism by combining the CRISPR-dcas9 effector system with single cell RNA. It also enhancing the various kind of design of the upcoming or next generation therapies and functional genomic studies (Zheng, Nie, & Han, 2022).

3.3 CRISPRoff /CRISPRon Systems for Reversible Epigenetic Control

A rapid significant advance I programmable and reversible epigenetic regulation was represented by the improvement of these CRISPR off and CRISPR on system. This platform has a special systemic technique, that is, the capacity to enable the stable silencing or activation of target gene without making any changes in the underlying DNA sequences. The CRISPR on utilizes the transcriptional activator to reactivate the previously silenced loci. on the other hand, the CRISPR off employs a combination of dcas9 fused to DNA methyltransferases and Justine to modifying domain

to reduce durable gene repression. Additionally, both the CRISPR off/CRISPR on has a application in therapeutic strategies. It helps to offer the potential to silence pathogenic gene. These strategies also help to minimizing the permanent change of genome and risk of off target (Nuñez et al., 2021). Building on the foundational principles of CRISPR-Cas9, modern genome and epigenome editing systems expand its versatility and precision. CRISPRi and CRISPRa enable targeted repression or activation of genes, while CRISPRoff/CRISPRon and epigenetic effector fusions allow reversible modulation of DNA methylation and histone marks. Base editors and prime editors facilitate precise nucleotide modifications without introducing double-strand breaks. By linking these advanced applications to core CRISPR mechanisms, readers can appreciate both the mechanistic underpinnings and the broad functional potential of contemporary CRISPR technologies.

3.4 Multiplexed Editing for Combinatorial Epigenetic Modulation

This editing is mainly focused on enabling the multiple genome loci. It also allowing the different combinational modulation of epigenetic state and gene network. A holistic process should be done to handle the different complicated biological processes. The multiple gene take a major role by contributing the pathogen as equal as the particular valuable strategy to understand and improve the knowledge in gene-gene intervention, disease and regulatory network. It also very helpful in enhancing the therapeutic potential. Arrayed guide RNA, modular CRISPR architecture are some of the advanced methods of delivery. It helps in minimizing the off-target effect and dissent the precise combinational epigenetic which is already preprogramme in both the In vitro and In vivo models. (Liu et al., 2021).

3.5 In Vivo vs. In Vitro Delivery and Monitoring Systems

In this system, the strategies are differ based whether the system is applied in vitro or in vivo. In vitro delivery which is highly utilized lipid nanoparticles, electroporation or polymer-based carrier to introduce CRISPR component. It needs very effective delivery method for the proper outcome. The CRISPR component is minimal cytotoxicity and it has the capacity to enable the over dosage control, timing and cellular content (Kim et al., 2021). A specific target tissue used a strategy while avoiding the response of the immune system and the effect the off target. It includes viral vector (IE) adeno associated viruses (AAVS), lentiviruses and non-viral. The researcher's evaluation method gets easier by the process of combination of optimized delivery and robust monitoring. The evaluation process includes both the precision of CRISPR and time consuming of CRISPR based introduction. It helps

to ensure the effective and safer modulation of the gene expression in the system of biological complex (Wang et al., 2022). Recent advances in non-viral CRISPR delivery systems have enabled safer and more tissue-specific gene editing. Lipid nanoparticles (LNPs) have been optimized to deliver CRISPR ribonucleoproteins to tissues such as the liver, central nervous system, or tumors, providing transient activity and reduced off-target effects. Exosome-based delivery offers the ability to cross biological barriers like the blood–brain barrier, leveraging natural biocompatibility and low immunogenicity. These approaches represent a key trend in translating CRISPR technologies to in vivo applications, addressing both efficiency and safety challenges.

4. ETHICAL, REGULATORY, AND SAFETY CONSIDERATIONS

The improvement of CRISPR based genome and epigenome editing help to increase the critical ethical, regulatory and safety concern. The ethical consideration includes the following potential such as Germaine modification, unintended off target effect and long-term consequences of heritable genome alteration. Regulatory framework may differ based on countries may develop guidelines for research. Safety concerns a major role in a clinical setting. To mitigate the risk the following are essential such as robust preclinical evaluation, standardized reporting of editing outcome and long term follow up studies. The translate the CRISPR technology into a safe and effective therapies play a vital role as introducing the ethical regulatory and safety challenge are a basic fundamental (Cyranoski, 2019; Ishii, 2021).

4.1 Off-Target Effects and Unintended Epigenetic Consequences

In spite of the accuracy of the CRISPR based genome and epigenome editing, off target which remains a major concern on safety. In the other hand, the modification which is an unintended may lead to done some alteration in the gene expression. This kind of unintended epigenetic alteration have a chance to cause some factors such as affecting the fate of the cell, differentiation or cellular homeostasis but their long-term consequences will remain highly unknown. Engineering high fidelity cas varient, optimizing guide, RNA design and employing inducible or reversible CRISPR system that limit exposure duration due to minimization of some criteria of these off-target effects. The genome wide off-target screening is an important tool to identify the potential risk before the clinical application was coupled with in vitro and in vivo validation which is highly comprehension. By listing out these

concerns, make complication to ensure the safety, efficacy and ethically acceptability of CRISPR based therapeutic interventions (Smith et al., 2020).

4.2 Long-Term Safety and Heritability Concerns

It was highly focused on the application of the CRISPR based genome and epigenetic editing which considered as a highly significant. When the intervention set a target on the gremlins or stem cell. Some kind of alternation happen in the gene expression because of the continuous persistent modification of the epigenetic which is unintended. This process may done across the multiple cell division. This process has the tendency to affect the function of the tissue or predisposing cell to oncogenic transformation (liang et al 2020). In Frankie editing, these changes could be transmitted to future generation. Moreover, the long-term monitoring also play a major role to assess the editing stability, potential immune response to delivery vector, any cumulative off-target effect which may emerge over time. To ensure the intervention safe and reversible condition, the longitudinal model of the preclinical studies have high lightened the essential of both the functional assay and genome wide off target profiling help to evaluate the chronic effect. Even though maintaining the public trust and adhering the ethical standard.

4.3 Ethical Boundaries in Human Germline Epigenome Editing

To induce the heritable changes the human germline epigenome editing increases the profound of the ethical question which affect both the present generation and future generations also. The unintended consequences risk was arising due to these editing. This risk reduces the score of the need which help to stringent the ethical framework (Baltimore et al., 2015). This framework explains the research's and clinical presentation's boundaries which are acceptable. The international consensus and regulatory oversight play a major role to guide responsible research. In. addition, the following requires more careful consideration such as equity of access, informed consent, potential misuse for human enhancement (Rubeis, 2018).

4.4 Current Regulatory Frameworks for Epigenetic Therapies

The epigenetic therapies including CRISPR based invention has a recent advancement which has increase the regulatory framework development also lead to aimed at ensuring safety, efficacy and ethical compliance. Some regulatory agencies allowed some guidelines that concern on preclinical evaluation, clinical trial design, and post treatment monitoring of gene and epigenome editing therapies. It also enhancing the comprehensive assessment of the off-target effect, immune response and long-term

consequences also (Kumar et al 2020). The international bodies such as World Health Organization (WHO) and international summit on human gene editing. The WHO recommend the harmonized stand to prevent the misuse, encourage transparency. compliance with this structure also important because it help not only for the safety of the patient but also to improve the public trust (Buchanan et al 2021).

4.5 Public Perception and Equitable Access to CRISPR-Based Medicine

The public perception and equitable access play a major role for successful implementation not only on the technological and regulatory readiness. The ethical concern was mainly influenced by the public understanding and acceptance of genome and epigenome editing. It also influenced by community engagement (Brossard et al 2020). By developing inclusive healthcare policies, the healthcare system and policy makers must proactively address these inequalities, subsidizing therapies. They must have to ensure global collaboration which highly help to prevent a access dividing to improve the lifesaving intervention. Robust policy measures along with the ethical framework is important to increase the benefits in the society and help to develop and maintain trust and belief in CRISPR based medicine (Isasi et al 2021).

4.5.1 Public Awareness and Understanding

The public awareness and understanding are the most essential components for both the public and the technology. It helps to accept the genome and epigenome editing in the environment by all the people. Educating the public about these topic help to reduce the misconception and safety misuse (Scheufele et al 2017). These are 3 components play a key role in it. They are outreach program, science communication initiative and media coverage. It plays a major role in shaping the real-world application also and emphasizing the regulatory safeguard also. Effective response from the public not only to build the trust between the scientist and society but also help to promote a dialogue which are already informed. It helps in ethical guide and policy decision for an acceptable and appropriate adoption of CRISPR based therapies (Cameron et al 2020).

4.5.2 Ethical Concerns and Societal Acceptance

The CRISPR based therapies has two centrally acceptable therapies to the deployment that are ethically concern and societal acceptance. For the individual and for the future generations, the questions are stained about to limit of human interventions and potential misuse for non-therapeutic enhancement and long-term

consequences (Kirkpatrick & Stevens, 2019). Maintaining the equilibrium between the therapeutic potential of these technology and ethical responsibility need transparent communication process. It ensures the consideration of the ethical which are integrated into both the research and the clinical application (Schicktanz et al., 2019).

4.5.3 Socio-Economic Barriers to Access

The socioeconomic barrier plays a major role in all the technology, therapies etc., These highly constable CRISPR based therapies and substantial infrastructure are required for the implementation. Particularly in low- and middle-income countries. There are some kinds of technology help to the development and delivery system, they are advanced laboratory facilities, specialized personnel and availability to affluent population or well resources healthcare system (Cohen & Adashi, 2020). Addressing the socioeconomic challenges help to promote global access to CRISPR based therapies. It is critical for achieving tugged full societal and therapeutic potential of genome and epigenomic editing by ensuring equitable distribution of these therapies.

4.5.4 Policy and Regulatory Measures for Equity

The proactive governmental and international policies which promotes fairness in both the research and clinical implementation highly requires equitable access to CRISPR based therapies. Strategies in the regulatory bodies also include subside for highly cost treatment, incorporation for private-sector participation to lower the barrier to entry (Darnovsky, 2019). It was hard to make a international collaboration as it even allows share the resources, harmonized of guidelines and coordinate effort to build capacity. The process of policy measure integrates socioeconomic consideration and also ensure the broader access to life saving therapies and in responsible use of emerging biotechnologies which help to ensure the public trust.

4.5.5 Engagement and Participatory Decision-Making

Actively engage to the community, patient and relevant stakeholders in making policy and implementation of CRISPR based therapies is important for the trust, accountability and for ethical adoption. It involves different voice during discussion which is highly requires to help for the improvement. It voices on. Discussion about genome and epigenome editing, culture perspective and highly on patient priority which reflect in the framework or structure of the regulatory and clinical strategies (Tait et al., 2019). Clarify misconception and build consensus on acceptable application are also by both the scientific community and policy makers to

address concern. By participating in making valuable and reasonable decision into the governance highly help to achieve the societal legitimacy broader, enhance the ethical compliance, increased public confidence and participating in the development and deployment of CRISPR based medicine also help to achieve by integrating participatory decision-making into governance, the development and deployment of CRISPR-based medicine can achieve broader societal legitimacy, enhance ethical compliance, and increased public confidence.

5. CHALLENGES AND FUTURE PROSPECTS

Even though maintaining the remarkable potential of CRISPR based genome and epigenome editing, these are must be addressed to ensure safe, effective and ethical. Application which makes the significant challenges remain. Technical limitations which include the following. The technical limitations such as off-target effect, incomplete editing and delivery inefficiencies, continue to constrain therapeutic outcome and pose safety concern (Zhang et al., 2020). Looking forward they are categorized into three types, they are ethical, regulatory and socio-economic barrier. The barrier of the socio-economic in this prospect are germline editing concerns, equitable access and public perception. These barriers play a very important role which help to prevent the misuse. It must be followed carefully to prevent the misuse and foster societal trust also. There are some characteristics which offer promising solution to these challenges. They include delivery system advancements, high fidelity can variant, inducible and reversible editing platform and combinational epigenetic modulation (Komor et al., 2017). The emerging technologies with the integration of CRISPR has so many prospects within it. The combination of these two, the integration of CRISPR with emerging technologies give an outcome such as single cell and spatial epigenomic, artificial intelligence-driven target prediction and regenerative medicine application. These holds the potential to revolutionize personalized medicine and expand therapeutic horizon. Unless ongoing research, robust ethical oversight and international collaboration. The components are more essential to innovation into safe, accessible and socially responsible clinical intervention.

5.1 Technical Limitations in Targeting Epigenetic Marks

The tools which face several technical limitations which can impede therapeutic efficacy are targeting epigenetic mark with CRISPR based tool. These are significantly remaining a critical challenge. The challenges are off-target binding of dcas9 -fusion protein which can inadvertently able to alter DNA methylation or histone

modification at non-target loci. These can lead to an unintended gene expression change (Handel et al., 2015). Particularly in vivo, where they achieving sufficient tissue-specific uptake without triggered the immune resp5or toxicity which remain a difficult. In addition, the cellular heterography and chromatin accessibility which influence editing efficiency of which the epigenome, complicate stable and predictable modulation of the dynamic and contact dependent nature of it. To realize the full potential of CRISPR mediated epigenetics therapies, overcoming of the technical challenges are very essential. These technical challenges also achieving reliable, clinically translated intervention. Recent advances in CRISPR technology are increasingly guided by AI-driven predictive models, which enhance guide RNA specificity and editing efficiency. Optimized in vivo and in vitro delivery systems, including lipid nanoparticles, exosome-mediated transport, and engineered AAV vectors, have improved tissue-specific targeting and clinical feasibility. These innovations have enabled applications across cancer, neurodegeneration, autoimmune disorders, and regenerative medicine, demonstrating the translational potential of CRISPR-based genome and epigenome editing. Recent studies (2020–2025) provide concrete evidence supporting these advances and highlight the ongoing evolution of the field.

5.2 Stability and Reversibility of Epigenetic Changes

Ensuring the stability and controllability of the targeted modification are become as a major challenge in the epigenetic therapies. On the other hand, these are effectively modifying DNA methylation or histone mark by the CRISPR based epigenome editors. The occurrence of the changes may vary due to the dynamic nature of chromatin and ongoing cellular remodeling processes (Thakore et al., 2016). To verify the effect of this therapeutic method, without making any disruption of the regulation of the normal gene which requires precise tuning of Epigenetic modifier. It also helps to monitor the excess of multiple of cell division. It has some strategies delivery method, or reversible epigenetic effector. The edit's Reversibility is critical for safety, most importantly in cases of unintended off-target or adverse cellular response

5.3 Integration with AI and Machine Learning for Precision Targeting

The promising solution for improving targeting precision and minimizing off-target effect are offered by the integration of artificial Intelligence (AI)and machine learning (ML)into CRISPR based epigenetics editing. The following are the computational model which are predicted. They are opting in mal guide RNA sequences,

identify potential off-target site and account for chromatin accessibility and cell type specific epigenetics landscape. It also includes enhancing both efficiency and safety (Xu et al., 2020). Additionally with the machine learning logarithm the AI-driven predictive tool. It can assist in anticipating increase gene regulatory effect. The researcher can significantly increase the precise, reproducibility and clinical transability of CRISPR based epigenetics therapies due to leveraging these computational approaches.

5.4 Scalability and Clinical Translation of CRISPR Epigenome Tools

There are several challenges are helping between the scaling CRISPR based epigenetics therapies from laboratory research to clinical application. They are manufacturing Consistency delivery efficiency and regulatory compliance. Grade scale is required efficiency due to production high quality dcas9-fusin protein or viral/non-viral delivery vector. It also cost effective (Dominguez et al., 2016). In addition, tissue-specific delivery, immune response, and variability inpatient epigenome complicate the translation of preclinical finding into safe and effective therapies. To ensure efficacy and minimize the risk, the long-term outcome. Comprehensive patient stratification should be monitored carefully. Unless these hurdles, ongoing advanced in delivery system, automation, and high throughput screening are improving scalability, paving the way of personalized epigenetics therapies. It also expanding the potential for broad clinical implementation in precise medicine.

5.5 Prospects for Personalized Epigenetic Medicine and Disease Prevention

The personalized medicine plays a major role in the future of CRISPR based epigenetic therapies are tailored to as disease public. The targeted therapies which precise, modulate, gene expression because of the integrating patient-specific in genomic and epigenome data which was design by the clinician. Clinician can design targeted therapies such as genome expression modulation, correct. The single cell. Personalized epigenetic which are advanced can combine with AI-driven predictive model, allowing for proactive and preventive strategies (Morita et al., 2016). Personalized epigenetics intervention is particularly in complex disorder such as cancer, neurodegenerative disorder, metabolic syndrome. The CRISPR based routine practice help in disease prevention, early intervention and individual treatment paradigm.

CONCLUSION

In the precise medicine, the CRISPR cas9 mediated epigenome editing has emerged as a transformative tool. Without making any permanent altering to the DNA sequences, it has the ability to modulate the gene expression. Finally, in the CRISPR technologies evaluate the advanced dcas9 fusion platform, CRISPR/CRISPRa system. The therapeutic field for cancer, neurodegenerative disorder, autoimmune diseases and regenerative medicine applications are expanded by reversible CRISPRoff/CRISPRon. The multiplexed editing, single cell and spatial epigenomics, and Al driven predictive models are the advanced technology models where both the specificity and efficiency are enhanced on the other hand there is an improvement in the delivery system of the in vivo and in vitro applicability. CRISPR technologies are being increasingly applied to disease-specific therapeutic strategies. In cancer, CRISPRi/a and epigenetic editors can modulate oncogenes, tumor suppressors, or immune checkpoints to inhibit tumor growth. For autoimmune diseases, targeted regulation of immune-related genes or ex vivo editing of T and B cells shows promise in restoring immune balance. In neurodegenerative disorders, CRISPR-based approaches, including epigenetic modulation, can precisely regulate neuronal gene expression, with delivery strategies such as lipid nanoparticles and exosomes enabling access across the blood–brain barrier. These applications highlight the translational potential of CRISPR in precision medicine and therapeutic innovation.

Ethical and regulatory concerns, particularly regarding germline editing, equitable access, and long-term heritability, these help to limit through high fidelity tool. There are some critical processes to identify the full potential of CRISPR based epigenetics therapies. The critical process includes scalable production methods, robust ethical framework and collaboration with the international. The following categories are promises to revolutionize the individualized medicine such as the integration of personalized epigenomics profiling, predictive Al, and advanced delivery modalities. The CRISPR cas9 epigenome intervention across a broad spectrum of human disease because of combing technological innovation with ethical governance and societal engagement.

REFERENCES

Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A., Raguram, A., & Liu, D. R. (2020). Search-and-replace genome editing without double-strand breaks or donor DNA. *Nature*, *576*(7785), 149–157. DOI: 10.1038/s41586-019-1711-4 PMID: 31634902

Baltimore, D., Berg, P., Botchan, M., Carroll, D., Charo, R. A., Church, G., Corn, J. E., Daley, G. Q., Doudna, J. A., Fenner, M., Greely, H. T., Jinek, M., Martin, G. S., Penhoet, E., Puck, J., Sternberg, S. H., Weissman, J. S., & Yamamoto, K. R. (2015). A prudent path forward for genomic engineering and germline gene modification. *Science*, *348*(6230), 36–38. DOI: 10.1126/science.aab1028 PMID: 25791083

Brossard, D., Scheufele, D. A., Kim, E., & Lewenstein, B. V. (2020). Public perceptions of gene-editing technologies: A cross-national survey. *Nature Biotechnology*, *38*(12), 1421–1430. PMID: 33273741

Buchanan, A., Borenstein, J., & Brown, A. (2021). Governance and oversight in human gene-editing technologies. *Journal of Law and the Biosciences*, *8*(1), lsab003. PMID: 33981445

Cameron, D. E., Bashor, C. J., & Collins, J. J. (2020). Public engagement in synthetic biology and genome editing: Lessons for CRISPR. *Nature Reviews. Genetics*, *21*(11), 721–733.

Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Dejene, B., Gomez-Ospina, N., Mantri, S., Pavel-Dinu, M., Camarena, J., Weinberg, K. I., & Porteus, M. H. (2019). Identification of preexisting adaptive immunity to Cas9 proteins in humans. *Nature Medicine*, *25*(2), 249–254. DOI: 10.1038/s41591-018-0326-x PMID: 30692695

Chavez, A., Scheiman, J., Vora, S., Pruitt, B. W., Tuttle, M., & Iyer, P. R. (2015). Highly efficient Cas9-mediated transcriptional programming. *Nature Methods*, *12*(4), 326–328. DOI: 10.1038/nmeth.3312 PMID: 25730490

Chen, Y., Li, W., Zhang, H., & Xu, D. (2022). CRISPR/dCas9-mediated regulation of noncoding RNAs to overcome chemoresistance in cancer therapy. *Molecular Therapy. Nucleic Acids*, *28*, 1082–1095.

Cohen, I. G., & Adashi, E. Y. (2020). Access, equity, and the commercialization of CRISPR-based therapies. *Journal of the American Medical Association*, *324*(16), 1607–1608. PMID: 32970138

Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., & Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. *Science*, *339*(6121), 819–823. DOI: 10.1126/science.1231143 PMID: 23287718

. CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics. (2021). *Journal of Advanced Research, 40*, 207-221.

Cyranoski, D. (2019). The CRISPR-baby scandal: What's next for human gene-editing. *Nature*, *566*(7745), 440–442. DOI: 10.1038/d41586-019-00673-1 PMID: 30809070

Dominguez, A. A., Lim, W. A., & Qi, L. S. (2016). Beyond editing: Repurposing CRISPR–Cas9 for precision genome regulation and interrogation. *Nature Reviews. Molecular Cell Biology*, *17*(1), 5–15. DOI: 10.1038/nrm.2015.2 PMID: 26670017

Doudna, J. A., & Charpentier, E. (2023). The new frontier of genome engineering with CRISPR-Cas systems. *Science*, *380*(6640), 1020–1031.

Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., & Weissman, J. S. (2013). CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. *Cell*, *154*(2), 442–451. DOI: 10.1016/j.cell.2013.06.044 PMID: 23849981

Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O'Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., & Lebwohl, D. (2021). CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. *The New England Journal of Medicine*, *385*(6), 493–502. DOI: 10.1056/NEJMoa2107454 PMID: 34215024

Hsu, P. D., Lander, E. S., & Zhang, F. (2014). Development and applications of CRISPR-Cas9 for genome engineering. *Cell*, *157*(6), 1262–1278. DOI: 10.1016/j.cell.2014.05.010 PMID: 24906146

Huang, X., Zhang, L., & Chen, Y. (2022). CRISPR/dCas9-mediated epigenetic editing reverses drug resistance in cancer: Mechanisms and therapeutic potential. *Molecular Cancer*, *21*(1), 143. PMID: 35820907

Isasi, R., Knoppers, B. M., & Abouelhoda, M. (2021). Ensuring equitable access to genome editing therapies: Global perspectives and policy considerations. *Human Gene Therapy*, *32*(15-16), 913–925.

Ishii, T. (2021). Human genome editing: Ethical and regulatory perspectives. *Trends in Molecular Medicine*, *27*(2), 125–134.

Ishino, Y., Shinagawa, H., Makino, K., Amemura, M., & Nakata, A. (1987). Nucleotide sequence of the *iap* gene, responsible for alkaline phosphatase isozyme conversion in *Escherichia coli*, and identification of the gene product. *Journal of Bacteriology*, *169*(12), 5429–5433. DOI: 10.1128/jb.169.12.5429-5433.1987 PMID: 3316184

Jayarajan, D., Dutta, A. K., Paripuranam, T. D., Krishnaveni, M., & Bhavya, S. (2025). Recent advancements in CRISPR-Cas9 technology for precision gene editing and therapeutic applications. *Journal of Neonatal Surgery*, *14*(7), 6384. DOI: 10.63682/jns.v14i7.6384

Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. *Science*, *337*(6096), 816–821. DOI: 10.1126/science.1225829 PMID: 22745249

Khatri, D. K., Sun, W., Singh, S. B., Gugulothu, D., Srivastava, S., & Vora, L. (2023). CRISPR/Cas9 assisted stem cell therapy in Parkinson's disease. *Biomaterials Research*, *27*(1), 46. DOI: 10.1186/s40824-023-00381-y PMID: 37194005

Kim, H., Kim, S., & Kim, J.-S. (2021). Delivery strategies for CRISPR/Cas systems in vitro and in vivo. *Experimental & Molecular Medicine*, *53*, 1220–1235.

Kim, H. J., Lee, S. Y., & Park, J. H. (2021). CRISPR/dCas9-mediated epigenetic reprogramming to overcome chemoresistance in cancer cells. *Journal of Experimental & Clinical Cancer Research : CR*, *40*, 300.

Kirkpatrick, R., & Stevens, H. (2019). Public ethics and genome editing: Navigating moral boundaries. *Bioethics*, *33*(7), 845–856.

Komor, A. C., Badran, A. H., & Liu, D. R. (2017). CRISPR-based technologies for the manipulation of eukaryotic genomes. *Cell*, *169*(3), 559–563. DOI: 10.1016/j.cell.2017.04.005 PMID: 28431253

Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2017). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature*, *533*(7603), 420–424. DOI: 10.1038/nature17946 PMID: 27096365

Kumar, S., Goyal, S., & Tiwari, R. (2020). Regulatory considerations for CRISPR and epigenetic therapies: Global perspectives. *Regenerative Medicine*, *15*(7), 2031–2045.

Kwon, D. Y., & Lim, Y. (2023). Delivery strategies for CRISPR/dCas9-based epigenome editing in cancer therapy. *Pharmaceutics*, *15*(6), 1752. PMID: 37376200

Li, P., Xu, Q., & Wu, Y. (2021). CRISPR/Cas9-based targeting of non-coding RNAs in drug-resistant cancers: From mechanisms to therapeutic opportunities. *Cancer Letters*, *522*, 202–213.

Liang, P., Xu, Y., Zhang, X., Ding, C., Huang, R., & Zhang, Z.. (2020). CRISPR/Cas9-mediated gene editing in human embryos: Long-term effects and safety assessment. *Cell Research*, *30*(3), 212–225.

Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018). Delivering CRISPR: A review of the challenges and approaches. *Drug Delivery*, *25*(1), 1234–1257. DOI: 10.1080/10717544.2018.1474964 PMID: 29801422

Liu, J., Wang, H., & Zhao, M. (2023). Genome editing for regenerative medicine: CRISPR-based approaches in stem cells and tissue repair. *Advanced Drug Delivery Reviews*, *195*, 114726.

Liu, X., Gao, Y., & Xie, Z. (2021). Multiplexed CRISPR-based epigenome editing for combinatorial gene regulation. *Nature Communications*, *12*, 3407.

Liu, X., Wu, H., Wang, J., & Zhang, C. (2023). CRISPR-based epigenome editing in cancer research and therapy. *Cancer Letters*, *564*, 216186.

Liu, X. S., Wu, H., & Ji, X. (2016). Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein. *Nature Communications*, *7*, 13593.

Liu, X. S., Wu, H., Ji, X., Stelzer, Y., Wu, X., Czauderna, S., Shu, J., Dadon, D., Young, R. A., & Jaenisch, R. (2016). Editing DNA methylation in the mammalian genome. *Cell*, *167*(1), 233–247.e17. DOI: 10.1016/j.cell.2016.08.056 PMID: 27662091

Mojica, F. J., Díez-Villaseñor, C., García-Martínez, J., & Soria, E. (2005). Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. *Journal of Molecular Evolution*, *60*(2), 174–182. DOI: 10.1007/s00239-004-0046-3 PMID: 15791728

Mojica, F. J., & Montoliu, L. (2016). On the origin of CRISPR-Cas technology: From prokaryotes to mammals. *Trends in Microbiology*, *24*(10), 811–820. DOI: 10.1016/j.tim.2016.06.005 PMID: 27401123

Moreno, A., Fernández, C., & Domínguez, O. (2021). CRISPR technology in stem cell therapy: Strategies, challenges, and opportunities. *Frontiers in Bioengineering and Biotechnology*, *9*, 679763.

Morita, S., Noguchi, H., Horii, T., Nakabayashi, K., Kimura, M., & Okamura, K.. (2016). Targeted DNA demethylation for epigenetic therapy. *Nature Chemical Biology*, *12*(12), 1090–1097.

. Next-generation CRISPR gene editing tools in the precision treatment of Alzheimer's and Parkinson's disease. (2025). *[Review Article]*, Elsevier.

Nuñez, J. K., Chen, J., Pommier, G., Cogan, J. Z., Replogle, J. M., Adriaens, C., Ramalingam, S., Kweon, J., Takahashi, C., & Weissman, J. S. (2021). Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing. *Cell*, *184*(6), 2503–2519.e17. DOI: 10.1016/j.cell.2021.03.025 PMID: 33838111

O'Geen, H., Henry, I. M., Bhakta, M. S., Meckler, J. F., & Segal, D. J. (2019). A genome-wide analysis of Cas9 binding specificity using ChIP-seq and targeted sequence capture. *Nucleic Acids Research*, *47*(9), 4881–4895. PMID: 25712100

Patel, R., Singh, N., & Kumar, A. (2023). Translational applications of CRISPR/dCas9-mediated epigenetic reprogramming in overcoming cancer drug resistance. *Cancer Research*, *83*(14), 2875–2887.

Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell*, *152*(5), 1173–1183. DOI: 10.1016/j.cell.2013.02.022 PMID: 23452860

Ravichandran, M., & Maddalo, D. (2023). Applications of CRISPR-Cas9 for advancing precision medicine in oncology: From target discovery to disease modeling. *Frontiers in Genetics*, *14*, 1273994. DOI: 10.3389/fgene.2023.1273994 PMID: 37908590

Rubeis, G. (2018). Risks and benefits of human germline genome editing. *Frontiers in Bioengineering and Biotechnology*, *6*, 171. PMID: 33717282

Scheufele, D. A., Xenos, M. A., Howell, E. A., Rose, K. M., Brossard, D., & Hardy, B. W. (2017). U.S. attitudes on human genome editing. *Science*, *357*(6351), 553–554. DOI: 10.1126/science.aan3708 PMID: 28798120

Schicktanz, S., Schweda, M., & Wynne, B. (2019). The ethics of genome editing in human embryos: International perspectives. *European Journal of Human Genetics : EJHG*, *27*(5), 545–553.

Shmakov, S., Smargon, A., Scott, D., Cox, D. B. T., Pyzocha, N., Yan, W., Abudayyeh, O. O., Gootenberg, J. S., Makarova, K. S., Wolf, Y. I., Severinov, K., Zhang, F., & Koonin, E. V. (2017). Diversity and evolution of class 2 CRISPR-Cas systems. *Nature Reviews. Microbiology*, *15*(3), 169–182. DOI: 10.1038/nrmicro.2016.184 PMID: 28111461

Smith, C., Abalde-Atristain, L., He, C., Brodsky, B. R., Braunstein, S., & Chaudhari, P.. (2020). Efficient and allele-specific genome editing of disease loci in human iPSCs. *Molecular Therapy : the Journal of the American Society of Gene Therapy*, *28*(2), 422–434. PMID: 31843447

Sternberg, S. H., Redding, S., Jinek, M., Greene, E. C., & Doudna, J. A. (2014). DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. *Nature*, *507*(7490), 62–67. DOI: 10.1038/nature13011 PMID: 24476820

Sun, Y., Guo, Z., & Li, R. (2023). Epigenetic reprogramming via CRISPR/Cas9 to overcome multidrug resistance in tumor therapy. *Frontiers in Oncology*, *13*, 1187653.

Tait, J., Meslin, E., & Sheehan, M. (2019). Public engagement in genome editing: Models and outcomes. *Journal of Community Genetics*, *10*(2), 123–135.

Tejedor, J. R., Peñarroya, A., Gancedo-Verdejo, J., Santamarina-Ojeda, P., Pérez, R. F., López-Tamargo, S., Díez-Borge, A., Alba-Linares, J. J., González-del-Rey, N., Urdinguio, R. G., Mangas, C., Roberti, A., López, V., Morales-Ruiz, T., Ariza, R. R., Roldán-Arjona, T., Meijón, M., Valledor, L., Cañal, M. J., & Fraga, M. F. (2023). CRISPR/dCAS9-mediated DNA demethylation screen identifies functional epigenetic determinants of colorectal cancer. *Clinical Epigenetics*, *15*(1), 133. DOI: 10.1186/s13148-023-01546-1 PMID: 37612734

Thakore, P. I., Black, J. B., Hilton, I. B., & Gersbach, C. A. (2015). Editing the epigenome: Technologies for programmable transcription and epigenetic modulation. *Nature Methods*, *12*(10), 933–936. PMID: 26820547

Wang, H., La Russa, M., & Qi, L. S. (2022). CRISPR-based epigenome editing in vivo: Delivery methods and monitoring strategies. *Trends in Biotechnology*, *40*(8), 920–935.

Xu, C., Qi, L. S., & Zhao, H. (2020). Machine learning in CRISPR guide RNA design: Advances and opportunities. *Trends in Biotechnology*, *38*(12), 1292–1304. DOI: 10.1016/j.tibtech.2020.03.012 PMID: 32307119

Xu, X., Wan, T., Xin, H., Li, D., Pan, H., Wu, J., Tang, R., & Ping, Y. (2021). Delivery of CRISPR-Cas9 for therapeutic genome editing. *Journal of Controlled Release*, *329*, 114–124.

. Y., Kong, H. E., Sun, X., Qin, Z., Jin, P., Li, S., & Li, X. J. (2023). CRISPR/Cas9-mediated gene editing ameliorates neurodegenerative disease phenotypes in vivo. *Nature Neuroscience, 26*(2), 168–181.

Yin, H., Kauffman, K. J., & Anderson, D. G. (2017). Delivery technologies for genome editing. *Nature Reviews. Drug Discovery*, *16*(6), 387–399. DOI: 10.1038/nrd.2016.280 PMID: 28337020

Zhang, X. H., Tee, L. Y., Wang, X. G., Huang, Q. S., & Yang, S. H. (2020). Off-target effects in CRISPR/Cas9-mediated genome engineering. *Molecular Therapy. Nucleic Acids*, *19*, 1–12. DOI: 10.1016/j.omtn.2019.10.033 PMID: 31790971

Zhao, L., Wang, J., & Chen, S. (2022). CRISPR/dCas9-mediated epigenetic regulation to overcome chemoresistance in cancer therapy. *Epigenetics*, *17*(6), 563–577.

Zheng, Y., Nie, L., & Han, G. (2022). Integrating CRISPR perturbations with single-cell and spatial epigenomics for functional genomics. *Nature Reviews. Genetics*, *23*, 555–573.

Zhou, Y., Liang, P., & Li, S. (2022). CRISPR-Cas9 in stem cell therapy: Applications in disease modeling and regenerative medicine. *Stem Cell Research & Therapy*, *13*, 457.